Game-changing gene therapies present cost problems for health execs – ModernMedicine
ModernMedicine |
Game-changing gene therapies present cost problems for health execs
ModernMedicine The recent approval of two cell-based gene therapies has healthcare executives scratching their heads about ways to manage these anticipated costly drugs, say experts. In August, the FDA approved Novartis's tisagenlecleucel (Kymriah), the first … |
